Ethical and legal implications of pharmacogenomics

Nature Reviews Genetics

Volumn 2, Issue 3, 2001, Pages 228-231

  Rothstein, Mark A ^a   Epps, Phyllis Griffin ^b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG LEGISLATION; GENETICS AND REPRODUCTION; GENOTYPE; HEALTH CARE AND PUBLIC HEALTH; HUMAN; LEGAL APPROACH; MEDICAL ETHICS; PHARMACOGENETICS; REVIEW;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION; HEALTH CARE AND PUBLIC HEALTH; LEGAL APPROACH;

CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; ETHICS, MEDICAL; GENOTYPE; HUMANS; LEGISLATION, DRUG; PHARMACOGENETICS;

EID: 0035286694     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/35056075     Document Type: Review

References (27)

1. Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279, 1200-1205 (1998).
2. Flanagan, A. Screening technologies evolve: innovations spurred by race to profit from genetic data. Genet. Eng. News 20, 1, 19-20, 71 (September 1, 2000).
3. Barrett, A. The pharma frenzy: in the race for gene-based therapies, big drugmakers join forces with upstarts. Business Week 160-161 (June 2000).
4. Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).
5. Noah, B. A. Adverse drug reactions: harnessing experiential data to promote patient welfare. Catholic U. Law Rev. 49, 449-504 (2000).
6. Roses, A. D. Pharmacogenetics and future drug development and delivery. Lancet 355, 1358-1361 (2000).
7. Richmond, M. H. et al. Human Genomics: Prospects for Health Care and Public Policy (Pharmaceutical Partners for Better Healthcare, England, 1999).
8. Wood, A. J. J. & Woosley, R. Making medicines safer -the need for an independent drug safety board. N. Engl. J. Med. 339, 1851-1853 (1998).
9. Rothstein, M. A. Genetic privacy and confidentiality: why they are so hard to protect. J. Law Med. Ethics 26, 198-204 (1998).
10. Meyer, U. A. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
11. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
12. Beutler, E. G6PD: population genetics and clinical manifestations. Blood Rev. 10, 45-52 (1996).
13. Weber, W. W. Pharmacogenetics Vol. 15 (Oxford Univ. Press, New York, 1997).
14. Grant, D. M. et al. Human acetyltransferase polymorphisms. Mutat Res. 376, 61-70 (1997).
15. Sharp, R. S. & Foster, M. W. Involving study populations in the review of genetic research. J. Law Med. Ethics 28, 41-50 (2000).
16. Juengst, E. T. Commentary: what 'community review' can and cannot do. J. Law Med. Ethics 28, 52-54 (2000).
17. Holmer, A. F. Correspondence: the pharmaceutical industry - to whom is it accountable? N. Engl. J. Med. 343, 1415 (2000).
18. Mrazek, M. F. & Mossialos, E. Increasing demand while decreasing costs of generic medicines. Lancet 356, 1784-1785 (2000).
19. Angell, M. The pharmaceutical industry - to whom is it accountable? N. Engl. J. Med. 342, 1902-1904 (2000).
20. Thamer, M. et al. A cross-national comparison of orphan drug policies: implications for the U. S. Orphan Drug Act. J. Hlth Politics Policy Law 23, 265-290 (1998).
21. Pulsinelli, G. A. The orphan drug act: what's right with it. Santa Clara Computer & High Technology Law J. 15, 299-345 (1999).
22. Kuszler, P. C. Financing clinical research and experimental therapies: payment due, but from whom? DePaul J. Hlth Care Law 3, 441-494 (2000).
23. Schoonmaker, M. M. et al. Factors influencing health insurers' decisions to cover new genetic technologies. Intl J. Technol. Assess. Hlth Care 16, 178-189 (2000).
24. Homer v. Spalitto, 1 S. W. 3d 519 (Mo. Ct. App. 1999) (reversing grant of summary judgement in favor of customer who died from overdose following accurate filling of incorrectly prescribed drug by pharmacist). Available at http://www.mobar.org/bulletin/nov99/bul-bod.htm
25. Cassidy v. Smithkline Beecham, No. 99-10423 (Pa. Chester County Dec. 14, 1999).
26. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report (April 18, 1979).
27. Emanuel, E. J., Wendler, D. & Grady, C. What makes clinical research ethical? J. Am. Med. Assoc. 283, 2701-2711 (2000).